Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn’s disease: a subanalysis of the DIAMOND trial.

Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn’s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017 Sep 08;: Authors: Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group Abstract BACKGROUND: Significance of monitoring adalimumab trough levels and anti-adalimumab antibodies (AAA) for disease outcome in Crohn’s disease (CD)…

Read More

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn’s disease.

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn’s disease. J Gastroenterol Hepatol. 2017 Aug 30;: Authors: Sugita N, Watanabe K, Kamata N, Yukawa T, Otani K, Hosomi S, Nagami Y, Tanaka F, Taira K, Yamagami H, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Kabata D, Shintani A, Arakawa T, Fujiwara Y Abstract BACKGROUND AND AIM: Secondary loss of response to adalimumab (ADA-LOR) commonly occurs in patients with Crohn’s disease (CD) treated with ADA. We evaluated the efficacy of…

Read More

Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea.

Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea. Dig Dis Sci. 2017 Aug 18;: Authors: Seo H, Ye BD, Song EM, Lee SH, Chang K, Lee HS, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND AND AIMS: Large-scale studies regarding the long-term outcomes of adalimumab (ADA) treatment in Asian patients with Crohn’s disease (CD) are still scarce. METHODS: We retrospectively analyzed the long-term outcomes of ADA treatment in Korean CD patients who commenced…

Read More

Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn’s Disease.

Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn’s Disease. Inflamm Bowel Dis. 2017 Aug 03;: Authors: Kariyawasam VC, Ward MG, Blaker PA, Patel KV, Goel R, Sanderson JD, Irving PM Abstract BACKGROUND: The benefit of concomitant immunomodulation with adalimumab (ADA) in Crohn’s disease is poorly understood. We aimed to compare ADA monotherapy with combination therapy with thiopurines, stratified by thioguanine nucleotides (TGNs). METHODS: Retrospective observational study of…

Read More

Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn’s Disease.

Related Articles Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2017 Aug;23(8):1316-1327 Authors: Chalhoub JM, Rimmani HH, Gumaste VV, Sharara AI Abstract BACKGROUND: It is unclear whether the combination of adalimumab (ADA) and immunomodulators is superior to ADA monotherapy in patients with Crohn’s disease. METHODS: PubMed, Medline, Embase, Web of Science, and other databases were searched. Randomized controlled trials, open-label, prospective cohort, and retrospective studies, and pooled analyses were included. Primary…

Read More

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice.

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. Inflamm Bowel Dis. 2017 Jul 12;: Authors: Aguas Peris M, Bosó V, Navarro B, Marqués-Miñana MR, Bastida G, Beltrán B, Iborra M, Sáez-González E, Monte-Boquet E, Poveda-Andrés JL, Nos P Abstract BACKGROUND: Little is known about the association between the pharmacokinetic features of adalimumab (ADL) and disease outcome in patients with inflammatory bowel disease (IBD). AIMS: To assess the association between random serum ADL levels and clinical or biochemical remission with clinical decision…

Read More

Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors.

Related Articles Infliximab and adalimumab drug levels in Crohn’s disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther. 2017 May 08;: Authors: Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM Abstract BACKGROUND: Discriminative drug level thresholds for disease activity endpoints in patients with Crohn’s disease. have been consistently demonstrated with infliximab, but not adalimumab. AIMS: To identify threshold concentrations for infliximab and adalimumab in Crohn’s disease according to different disease endpoints,…

Read More

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Related Articles Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2017 Apr 12;: Authors: Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M PMID: 28405767 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28405767?dopt=Abstract

Read More
<< Go Back